المؤلفون: M. I. Strokova, T. B. Morgunova, V. V. Fadeev, М. И. Строкова, Т. Б. Моргунова, В. В. Фадеев

المصدر: Meditsinskiy sovet = Medical Council; № 23 (2023); 202-207 ; Медицинский Совет; № 23 (2023); 202-207 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: пандемия, de Quervain thyroiditis, thyrotoxicosis, SARS-CoV-2, pandemic, тиреоидит де Кервена, тиреотоксикоз

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/8019/7111Test; Poorolajal J. The global pandemics are getting more frequent and severe. J Res Health Sci. 2021;21(1):e00502. https://doi.org/10.34172/jrhs.2021.40Test.; Stasiak M, Lewiński A. New aspects in the pathogenesis and management of subacute thyroiditis. Rev Endocr Metab Disord. 2021;22(4):1027–1039. https://doi.org/10.1007/s11154-021-09648-yTest.; Gorini F, Vassalle C. A Literature review on SARS-CoV-2 and other viruses in thyroid disorders: environmental triggers or no-guilty bystanders? Int J Environ Res Public Health. 2023;20(3):2389. https://doi.org/10.3390/ijerph20032389Test.; Desailloud R, Hober D. Viruses and thyroiditis: an update. Virol J. 2009;6:5. https://doi.org/10.1186/1743-422X-6-5Test.; Brancatella A, Ricci D, Viola N, Sgrò D, Santini F, Latrofa F. Subacute thyroiditis after Sars-COV-2 infection. J Clin Endocrinol Metab. 2020;105(7):dgaa276. https://doi.org/10.1210/clinem/dgaa276Test.; Tabassom A, Chippa V, Edens MA. De Quervain Thyroiditis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK526066Test.; Mundy-Baird G, Kyriacou A, Syed AA. De Quervain subacute thyroiditis. CMAJ. 2021;193(26):E1007. https://doi.org/10.1503/cmaj.202787Test.; Martinez Quintero B, Yazbeck C, Sweeney LB. Thyroiditis: Evaluation and Treatment. Am Fam Physician. 2021;104(6):609–617. Available at: https://pubmed.ncbi.nlm.nih.gov/34913664Test.; Fatourechi V, Aniszewski JP, Fatourechi GZ, Atkinson EJ, Jacobsen SJ. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab. 2023;88(5):2100–2105. https://doi.org/10.1210/jc.2002-021799Test.; Alfadda AA, Sallam RM, Elawad GE, Aldhukair H, Alyahya MM. Subacute thyroiditis: clinical presentation and long term outcome. Int J Endocrinol. 2014;794943. https://doi.org/10.1155/2014/794943Test.; Görges J, Ulrich J, Keck C, Müller-Wieland D, Diederich S, Janssen OE. Longterm outcome of subacute thyroiditis. Exp Clin Endocrinol Diabetes. 2020;128(11):703–708. https://doi.org/10.1055/a-0998-8035Test.; Hepşen S, Saat H, Akhanli P, Cakal E. The management of repetitive subacute thyroiditis in a male patient having HLA-B35:01 and B41:02 alleles. Acta Endocrinol (Buchar). 2022;18(4):512–515. https://doi.org/10.4183/aeb.2022.512Test.; Yasuda S, Suzuki S, Yanagisawa S, Morita H, Haisa A, Satomura A et al. HLA typing of patients who developed subacute thyroiditis and Graves’ disease after SARS-CoV-2 vaccination: a case report. BMC Endocr Disord. 2023;23(1):54. https://doi.org/10.1186/s12902-023-01287-5Test.; Stasiak M, Tymoniuk B, Stasiak B, Lewiński A. The risk of recurrence of subacute thyroiditis is HLA-dependent. Int J Mol Sci. 2019;20(5):1089. https://doi.org/10.3390/ijms20051089Test.; Ray I, D’Souza B, Sarker P, Agarwal P. Management of subacute thyroiditis – a systematic review of current treatment protocols. Int J Gen Med. 2022;15:6425–6439. https://doi.org/10.2147/IJGM.S366784Test.; Muller I, Cannavaro D, Dazzi D, Covelli D, Mantovani G, Muscatello A et al. SARS-CoV-2-related atypical thyroiditis. Lancet Diabetes Endocrinol. 2020;8(9):739–741. https://doi.org/10.1016/S2213-8587Test(20)30266-7.; Mattar SAM, Koh SJQ, Rama Chandran S, Cherng BPZ. Subacute thyroiditis associated with COVID-19. BMJ Case Rep. 2020;13(8):e237336. https://doi.org/10.1136/bcr-2020-237336Test.; Rotondi M, Coperchini F, Ricci G, Denegri M, Croce L, Ngnitejeu ST et al. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis. J Endocrinol Invest. 2021;44(5):1085–1090. https://doi.org/10.1007/s40618-020-01436-wTest.; Lazarus JH. Silent thyroiditis and subacute thyroiditis. In: Braverman LE, Utiger RD (eds.). The Thyroid: A Fundamental and Clinical Text. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 1996. 577 р.; Тимофеева ЛА, Александров ЮК, Алешина ТН, Юсова МА. Подострый тиреоидит, ассоциированный с COVID-19. Российский электронный журнал лучевой диагностики. 2021;11(3):15–24. https://doi.org/10.21569/2222-7415-2021-11-3-15-24Test.; Chen Y, Zhu S, Chen H, Yao L, Zhou J, Xu Y et al. Diagnostic value of color doppler ultrasonography in subacute thyroiditis. Scanning. 2022:7456622. https://doi.org/10.1155/2022/7456622Test.; Cappelli C, Pirola I, Gandossi E, Formenti AM, Agosti B, Castellano M. Ultrasound findings of subacute thyroiditis: a single institution retrospective review. Acta Radiol. 2014;55(4):429–433. https://doi.org/10.1177/0284185113498721Test.; Lee YJ, Kim DW. Sonographic characteristics and interval changes of subacute thyroiditis. J Ultrasound Med. 2016;35(8):1653–1659. https://doi.org/10.7863/ultra.15.09049Test.; Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348(26):2646–2655. https://doi.org/10.1056/NEJMra021194Test.; Aemaz Ur Rehman M, Farooq H, Ali MM, Ebaad Ur Rehman M, Dar QA, Hussain A. The association of subacute thyroiditis with COVID-19: a systematic review. SN Compr Clin Med. 2021;3(7):1515–1527. https://doi.org/10.1007/s42399-021-00912-5Test.; Christensen J, O’Callaghan K, Sinclair H, Hawke K, Love A, Hajkowicz K, Stewart AG. Risk factors, treatment and outcomes of subacute thyroiditis secondary to COVID-19: a systematic review. Int Med J. 2022;52(4):522–529. https://doi.org/10.1111/imj.15432Test.; Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino Ch, Hasell J et al. Coronavirus Pandemic (COVID-19). 2020.; Wijenayake UN, Ratnayake GM, Abeyratne D, Bulugahapitiya US. A case report of subacute thyroiditis after inactivated SARS-CoV-2 vaccine. SAGE Open Med Case Rep. 2022;10:2050313X221140243. https://doi.org/10.1177/2050313X221140243Test.; Plaza-Enriquez L, Khatiwada P, Sanchez-Valenzuela M, Sikha A. A case report of subacute thyroiditis following mRNA COVID-19 vaccine. Case Rep Endocrinol. 2021:8952048. https://doi.org/10.1155/2021/8952048Test.; Adelmeyer J, Goebel JN, Kauka A, Kann PH. Two case reports of subacute thyroiditis after receiving vaccine for COVID-19. Case Rep Endocrinol. 2022:2022:3180004. https://doi.org/10.1155/2022/3180004Test.; Frangos S, Haralambous H, Michael K, Economides PA. Subacute thyroiditis after the third dose of the COVID-19 mRNA vaccine. Case report. Hell J Nucl Med. 2022:25(2):210–212. https://doi.org/10.1967/s002449912481Test.; Cohen Tervaert JW, Martinez-Lavin M, Jara LJ, Halpert G, Watad A, Amital H, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) in 2023. Autoimmun Rev. 2023;22(5):103287. https://doi.org/10.1016/j.autrev.2023.103287Test.; Pulendran B, Arunachalam PS, O’Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021;20(6):454–475. https://doi.org/10.1038/s41573-021-00163-yTest.; Facciolà A, Visalli G, Laganà A, Di Pietro A. An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives. Vaccines (Basel). 2022;10(5):819. https://doi.org/10.3390/vaccines10050819Test.; Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020;217:108480. https://doi.org/10.1016/j.clim.2020.108480Test.; Pipitone G, Rindi LV, Petrosillo N, Foti NAM, Caci G, Iaria C et al. Vaccine-induced subacute thyroiditis (De Quervain’s) after mRNA vaccine against SARS-CoV-2: a case report and systematic review. Infect Dis Rep. 2022;14(1):142–154. https://doi.org/10.3390/idr14010018Test.; Oğuz SH, Şendur SN, İremli BG, Gürlek A, Erbas T, Ünlütürk U. SARS-CoV-2 vaccine-induced thyroiditis: safety of revaccinations and clinical follow-up. J Clin Endocrinol Metab. 2022;107(5):e1823–e1834. https://doi.org/10.1210/Clinem/dgac049Test.; Bahçecioğlu AB, Karahan ZC, Aydoğan BI, Kalkan IA, Azap A, Erdoğan MF. Subacute thyroiditis during the COVID-19 pandemic: a prospective study. J Endocrinol Invest. 2022;45(4):865–874. https://doi.org/10.1007/s40618021-01718-xTest.; Sarker R, Roknuzzaman ASM, Nazmunnahar Hossain MJ, Islam MR. Benefits and probable ill effects of WHO’s declaration of end of COVID-19 pandemic: a way back to pandemic-free normal life. Ann Med Surg (Lond). 2023;85(6):3199–3201. https://doi.org/10.1097/MS9.0000000000000848Test.; https://www.med-sovet.pro/jour/article/view/8019Test

الإتاحة: https://doi.org/10.21518/ms2023-473Test
https://doi.org/10.34172/jrhs.2021.40Test
https://doi.org/10.1007/s11154-021-09648-yTest
https://doi.org/10.1186/1743-422X-6-5Test
https://doi.org/10.1210/clinem/dgaa276Test
https://doi.org/10.1503/cmaj.202787Test
https://doi.org/10.1210/jc.2002-021799Test
https://doi.org/10.1155/2014/794943Test
https://doi.org/10.1055/a-0998-8035Test
https://doi.org/10.4183/aeb.2022.512Test

المؤلفون: T. B. Morgunova, I. V. Glinkina, E. D. Pesheva, A. A. Zorina, V. V. Fadeev, Т. Б. Моргунова, И. В. Глинкина, Е. Д. Пешева, А. А. Зорина, В. В. Фадеев

المصدر: Meditsinskiy sovet = Medical Council; № 13 (2023); 122-129 ; Медицинский Совет; № 13 (2023); 122-129 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: терапевтическое применение, glucose lowering drug, metformin, glycemic control, therapeutic use, сахароснижающий препарат, метформин, гликемический контроль

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7720/6855Test; Дедов И.И., Шестакова М.В., Майоров А.Ю. (ред.). Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 11-й выпуск. М.; 2023. 234 с. Режим доступа: https://webmed.irkutsk.ru/doc/pdf/algosd.pdfTest.; Montvida O., Shaw J., Atherton J.J., Stringer F., Paul S.K. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes. Diabetes Care. 2018;41(1):69–78. https://doi.org/10.2337/dc17-1414Test.; Maruthur N.M., Tseng E., Hutfless S., Wilson L.M., Suarez-Cuervo C., Berger Z. et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med. 2016;164(11):740–751. https://doi.org/10.7326/M15-2650Test.; Fang M., Wang D., Coresh J., Selvin E. Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018. N Engl J Med. 2021;384(23):2219–2228. https://doi.org/10.1056/NEJMsa2032271Test.; Hadden D.R. Goat’s rue – French lilac – Italian fitch – Spanish sainfoin: gallega officinalis and metformin: the Edinburgh connection. J R Coll Physicians Edinb. 2005;35(3):258–260. Available at: https://pubmed.ncbi.nlm.nih.gov/16402501Test.; Keeler R.F., Baker D.C., Evans J.O. Individual animal susceptibility and its relationship to induced adaptation or tolerance in sheep to Galega officinalis L. Vet Hum Toxicol. 1988;30(5):420–423. Available at: https://pubmed.ncbi.nlm.nih.gov/3188360Test.; Bailey C.J., Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care. 1989;12(8):553–564. https://doi.org/10.2337/diacare.12.8.553Test.; Mckendry J.B., Kuwayti K., Rado P.P. Clinical experience with DBI (phenformin) in the management of diabetes. Can Med Assoc J. 1959;80(10):773–778. Available at: https://pubmed.ncbi.nlm.nih.gov/13652024Test.; Bailey C.J. Metformin: historical overview. Diabetologia. 2017;60(9):1566–1576. https://doi.org/10.1007/s00125-017-4318-zTest.; IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med. 2006;23(6):579–593. https://doi.org/10.1111/j.1464-5491.2006.01918.xTest.; Смирнова О.М. Место метформина в современном лечении и профилактике сахарного диабета 2 типа. Сахарный диабет. 2010;13(3):83–90. https://doi.org/10.14341/2072-0351-5494Test.; American Diabetes Association. Standards of Medical Care in Diabetes – 2021. Diabetes Care. 2021;44(Suppl. 1):111–124. https://doi.org/10.2337/dc21-S009Test.; Garber A.J., Handelsman Y., Grunberger G., Einhorn D., Abrahamson M.J., Barzilay J.I. et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2020. Endocr Pract. 2020;26(1):107–139. https://doi.org/10.4158/CS-2019-0472Test.; Cosentino F., Grant P.J., Aboyans V., Bailey C.J., Ceriello A., Delgado V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486Test.; Blonde L., Umpierrez G.E., Reddy S.S., McGill J.B., Berga S.L., Bush M. et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan – 2022 Update. Endocr Pract. 2022;28(10):923–1049. https://doi.org/10.1016/j.eprac.2022.08.002Test.; Sanchez-Rangel E., Inzucchi S.E. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586–1593. https://doi.org/10.1007/s00125-017-4336-xTest.; Hostalek U., Gwilt M., Hildemann S. Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. Drugs. 2015;75(10):1071–1094. https://doi.org/10.1007/s40265-015-0416-8Test.; Matthews D.R., Paldánius P.M., Proot P., Chiang Y., Stumvoll M., Del Prato S.; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519–1529. https://doi.org/10.1016/S0140-6736Test(19)32131-2.; Sivitz W.I., Phillips L.S., Wexler D.J., Fortmann S.P., Camp A.W., Tiktin M. et al. Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. Diabetes Care. 2020;43(5):940–947. https://doi.org/10.2337/dc19-1769Test.; Garber A.J., Duncan T.G., Goodman A.M., Mills D.J., Rohlf J.L. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103(6):491–497. https://doi.org/10.1016/s0002-9343Test(97)00254-4.; Mahabaleshwarkar R., DeSantis A. Metformin dosage patterns in type 2 diabetes patients in a real-world setting in the United States. Diabetes Res Clin Pract. 2021;172:108531. https://doi.org/10.1016/j.diabres.2020.108531Test.; Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104–112. https://doi.org/10.14341/DM2004116-17Test.; Ali M.K., Bullard K.M., Saydah S., Imperatore G., Gregg E.W. Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988–2014. Lancet Diabetes Endocrinol. 2018;6(5):392–403. https://doi.org/10.1016/S2213-8587Test(18)30027-5.; Vistisen D., Witte D.R., Brunner E.J., Kivimäki M., Tabák A., Jørgensen M.E., Færch K. Risk of Cardiovascular Disease and Death in Individuals With Prediabetes Defined by Different Criteria: The Whitehall II Study. Diabetes Care. 2018;41(4):899–906. https://doi.org/10.2337/dc17-2530Test.; Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012;35(4):731–737. https://doi.org/10.2337/dc11-1299Test.; Diabetes Prevention Program Research Group. Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2019;42(4):601–608. https://doi.org/10.2337/dc18-1970Test.; Walker E.A., Gonzalez J.S., Tripputi M.T., Dagogo-Jack S., Matulik M.J., Montez M.G. et al. Group. Long-term metformin adherence in the Diabetes Prevention Program Outcomes Study. BMJ Open Diabetes Res Care. 2020;8(1):e001537. https://doi.org/10.1136/bmjdrc-2020-001537Test.; Hughes A., Khan T., Kirley K., Moin T., Mainous A., Sachdev N. et al. Metformin Prescription Rates for Patients with Prediabetes. J Am Board Fam Med. 2022;35(4):821–826. https://doi.org/10.3122/jabfm.2022.04.210485Test.; McCreight L.J., Bailey C.J., Pearson E.R. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426–435. https://doi.org/10.1007/s00125015-3844-9Test.; Bonnet F., Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab. 2017;19(4):473–481. https://doi.org/10.1111/dom.12854Test.; Wee A.K.H., Sultana R. Determinants of vitamin B12 deficiency in patients with type-2 diabetes mellitus – A primary-care retrospective cohort study. BMC Prim Care. 2023;24(1):102. https://doi.org/10.1186/s12875-023-02057-xTest.; Rathis T.S., Ranganathan R.S., Solai Raja M., Srivastav P.S.S. Prevalence of Vitamin B12 Deficiency in Type 2 Diabetes Mellitus Patients on Metformin Therapy. Cureus. 2023;15(4):e37466. https://doi.org/10.7759/cureus.37466Test.; Kim J., Ahn C.W., Fang S., Lee H.S., Park J.S. Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes. Medicine (Baltimore). 2019;98(46):e17918. https://doi.org/10.1097/MD.0000000000017918Test.; Aroda V.R., Edelstein S.L., Goldberg R.B., Knowler W.C., Marcovina S.M., Orchard T.J. et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754–1761. https://doi.org/10.1210/jc.2015-3754Test.; Liu L., Simon B., Shi J., Mallhi A.K., Eisen H.J. Impact of diabetes mellitus on risk of cardiovascular disease and all-cause mortality: Evidence on health outcomes and antidiabetic treatment in United States adults. World J Diabetes. 2016;7(18):449–461. https://doi.org/10.4239/wjd.v7.i18.449Test.; Khunti K., Millar-Jones D. Clinical inertia to insulin initiation and intensification in the UK: A focused literature review. Prim Care Diabetes. 2017;11(1):3–12. https://doi.org/10.1016/j.pcd.2016.09.003Test.; Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854865. Available at: https://pubmed.ncbi.nlm.nih.gov/9742977Test.; Hong J., Zhang Y., Lai S., Lv A., Su Q., Dong Y. et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36(5):1304–1311. https://doi.org/10.2337/dc12-0719Test.; Selvin E., Bolen S., Yeh H.C., Wiley C., Wilson L.M., Marinopoulos S.S. et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168(19):2070–2080. https://doi.org/10.1001/archinte.168.19.2070Test.; Han Y., Xie H., Liu Y., Gao P., Yang X., Shen Z. Effect of metformin on allcause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019;18(1):96. https://doi.org/10.1186/s12933-019-0900-7Test.; Kim Y., Kim H.S., Lee J.W., Kim Y.S., You H.S., Bae Y.J. et al. Metformin use in el der ly population with diabetes reduced the risk of dementia in a dose-dependent manner, based on the Korean NHIS-HEALS cohort. Diabetes Res Clin Pract. 2020;170:108496. https://doi.org/10.1016/j.diabres.2020.108496Test.; Zhang Q.Q., Li W.S., Liu Z., Zhang H.L., Ba Y.G., Zhang R.X. Metformin therapy and cognitive dysfunction in patients with type 2 diabetes: A meta-analysis and systematic review. Medicine (Baltimore). 2020;99(10):e19378. https://doi.org/10.1097/MD.0000000000019378Test.; https://www.med-sovet.pro/jour/article/view/7720Test

الإتاحة: https://doi.org/10.21518/ms2023-211Test
https://doi.org/10.2337/dc17-1414Test
https://doi.org/10.7326/M15-2650Test
https://doi.org/10.1056/NEJMsa2032271Test
https://doi.org/10.2337/diacare.12.8.553Test
https://doi.org/10.1007/s00125-017-4318-zTest
https://doi.org/10.1111/j.1464-5491.2006.01918.xTest
https://doi.org/10.14341/2072-0351-5494Test
https://doi.org/10.2337/dc21-S009Test
https://doi.org/10.4158/CS-2019-0472Test